Rx Drug Ads: Number Of Side Effects, Price-Comparison Claims Impact Risk Perception
Executive Summary
Commercials citing non-severe side effects dilute message, London study concludes; US FDA finds price comparison claims may cause physicians to think a drug's risks are less severe and that risk info is less prominent on mobile devices.
You may also be interested in...
Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads
Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.